Trav16dv11 inhibitors are a specialized class of chemical compounds designed to interact with the Trav16dv11 protein or receptor, inhibiting its biological activity by targeting specific functional regions of the protein. These inhibitors typically work by binding to the active site of Trav16dv11, preventing the natural substrate or ligand from accessing the site and disrupting the protein's role in its associated biochemical pathway. Some Trav16dv11 inhibitors may also bind to allosteric sites-regions distinct from the active site-that cause conformational changes in the protein, altering its structure and thereby reducing its functional activity. The binding of these inhibitors is usually stabilized by non-covalent interactions such as hydrogen bonds, hydrophobic interactions, ionic forces, and van der Waals interactions. The precise nature and strength of these interactions depend on the structural compatibility between the inhibitor and the protein, which is a key factor in the efficiency of inhibition.
Structurally, Trav16dv11 inhibitors can range from small organic molecules to more complex compounds, depending on the specificity and affinity required for the target protein. These inhibitors often contain functional groups such as hydroxyl, amine, or carboxyl, which can form critical interactions with amino acid residues within the Trav16dv11 binding pocket. Additionally, aromatic rings and heterocycles may be incorporated to enhance hydrophobic interactions with non-polar regions of the protein. The physicochemical properties of these inhibitors, such as molecular weight, polarity, and solubility, are carefully optimized to ensure effective binding to the Trav16dv11 protein while maintaining stability in biological environments. Hydrophilic groups within the inhibitors may engage in hydrogen bonding with polar residues, while hydrophobic regions may promote binding in non-polar areas of the protein, contributing to the overall stability and efficacy of the inhibitor-protein complex. This structural diversity allows Trav16dv11 inhibitors to be fine-tuned for optimal interaction with the Trav16dv11 protein, ensuring efficient modulation of its activity.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $315.00 | ||
Palbociclib is a cyclin-dependent kinase (CDK) inhibitor that can inhibit CDK4/6 involved in cell cycle regulation. If Trav16dv11 is involved in cell cycle progression, palbociclib would impede its function by halting the cell cycle before it can act. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
Y-27632 is a ROCK inhibitor that can interfere with the Rho/ROCK pathway. By inhibiting this pathway, the function of Trav16dv11 would be inhibited if it relies on cytoskeletal rearrangements facilitated by the Rho/ROCK pathway for its activity. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $80.00 $212.00 $408.00 | 48 | |
SB431542 is an inhibitor of the TGF-β receptor. It would inhibit Trav16dv11 function by blocking the TGF-β signaling pathway, which may be crucial for the protein's functional role in cellular processes such as proliferation, differentiation, or apoptosis. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor that would inhibit the PI3K/AKT/mTOR pathway, which is central to many cellular processes. Inhibition of this pathway would thus inhibit Trav16dv11 if the protein's function is dependent on signals propagated through PI3K/AKT/mTOR. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is an mTOR inhibitor which would inhibit Trav16dv11 by arresting downstream signaling required for protein synthesis and other cellular processes essential for Trav16dv11's function. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
Gefitinib is an EGFR inhibitor and would inhibit Trav16dv11 by blocking EGFR signaling, which might be essential for the protein's role in cell growth and survival signaling pathways. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $112.00 $163.00 $928.00 | 19 | |
Trametinib is a MEK inhibitor that would impede the MAPK/ERK pathway, which could be necessary for Trav16dv11's function in cell differentiation, proliferation, or survival. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Sorafenib is a tyrosine kinase inhibitor that would inhibit Trav16dv11 by targeting multiple tyrosine kinases involved in the RAF/MEK/ERK pathway, potentially crucial for the protein's activity. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $25.00 $117.00 $209.00 | 27 | |
Imatinib is a tyrosine kinase inhibitor known to inhibit BCR-ABL, c-KIT, and PDGFR. Inhibition of these kinases would lead to the inhibition of Trav16dv11 if it is functionally related to signaling pathways involving these kinases. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Bortezomib is a proteasome inhibitor that would inhibit Trav16dv11 by preventing the degradation of regulatory proteins that control Trav16dv11 function, leading to its functional inhibition. |